Evolution in the dispensation of drugs for Alzheimer's disease after removal from the list of reimbursable drugs in France-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evolution in the dispensation of drugs for Alzheimer's disease after removal from the list of reimbursable drugs in France

Published:2021-04-05 Issue:8 Volume:69 Page:2350-2352
ISSN:0002-8614
Container-title:Journal of the American Geriatrics Society
language:en
Short-container-title:J Am Geriatr Soc

Author:

Noël Victor¹,Mouchoux Christelle¹²³,Krolak‐Salmon Pierre¹²⁴,Novais Teddy¹³⁵

Affiliation:

1. Université Lyon 1 Lyon France

2. INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon Lyon France

3. Service Pharmaceutique, Hôpital des Charpennes Hospices Civils de Lyon Lyon France

4. Centre Mémoire Ressource et Recherche de Lyon (CMRR), Hôpital des Charpennes Hospices Civils de Lyon Lyon France

5. Université Claude Bernard Lyon 1 Research on Healthcare Performance (RESHAPE), INSERM U1290 Lyon France

Publisher

Wiley

Subject

Geriatrics and Gerontology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgs.17151

Reference8 articles.

1. Removal of Drugs for Alzheimer’s Disease from the List of Reimbursable Drugs in France: Analysis of Change in Drug Use, Disease Management and Cognition Using the National Alzheimer Data Bank (BNA)

2. Cholinesterase Inhibitor Discontinuation in Patients With Alzheimer’s Disease

3. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses

4. Donepezil for dementia due to Alzheimer's disease;Birks JS;Cochrane Database Syst Rev,2018

5. Acetylcholinesterase inhibitors and risk of stroke and death in people with dementia

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of modifications to antidementia drug reimbursement in France: Analysis of the FRA‐DEM cohort;British Journal of Clinical Pharmacology;2024-06-26

2. Ten-Year Trends in Sales of Alzheimer Disease Drugs in France Compared With Sales in Germany, Spain, and the UK;JAMA Health Forum;2022-08-05

3. Des traitements symptomatiques qui ne sont plus remboursés mais qui sont toujours utilisés dans la maladie d’Alzheimer : pourquoi ?;La Presse Médicale Formation;2022-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3